UNASSIGNED: 129 Background: @entity1205 / @entity229 (DP) plus bevacizumab (B) demonstrated a superior progression-free survival (PFS) but did not prolong @entity1349 ( @entity1349 ) in comparison to DP monotherapy in CALGB 90401, a study of 1,050 @entity1 with metastatic @entity263 ( @entity263 ) who had not received prior chemotherapy for metastatic disease. @entity286 use increases VEGF levels, suggesting the benefit of bevacizumab may be greater in @entity1 who use @entity286 . METHODS: The association of @entity286 usage and @entity1349 was evaluated. @entity1 -reported history of @entity286 usage was prospectively collected for @entity1 on CALGB 90401. Within each smoking status group, the log-rank test was used to compare the survival time between the two treatment arms. The proportional hazards model was used to test for smoking by treatment interaction predicting @entity1349 . RESULTS: Of 865 @entity1 with available smoking history, 21%, 30% and 49% were current, former, and never smokers. As summarized in the table below, there was a non-statistically significant improvement in @entity1349 for current smokers treated on the DP+B arm compared to the DP arm. However, treatment-by-smoking interaction was not statistically significant in predicting @entity1349 (p=0.299). CONCLUSIONS: There was a trend toward an improvement in @entity1349 for current smokers treated with DP+B. The accuracy of @entity1 -reported smoking status will be confirmed with serum @entity4874 levels in a pilot study. The effect of @entity286 use on cancer outcomes with VEGF targeted therapy will be evaluated in other @entity5 .

Evaluating the effect of @entity286 on XXXX outcomes with VEGF-targeted therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient'] @entity286 :: ('4097', 'Species') :: ['tobacco', 'Tobacco'] @entity263 :: ('MESH:D011471', 'Disease') :: ['castration-resistant prostate cancer', 'CRPC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity4874 :: ('MESH:D003367', 'Chemical') :: ['cotinine'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
